Table 1 General linear model analysis comparing placebo and omega-3 PUFA groups in terms of change between baseline and follow-up after adjusting for baseline score, site, and baseline MADRS score

From: NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders—medium-term follow-up and clinical course

 

n

Baseline (mean)

Medium-term follow-up (mean)

Medium-term—BL change (mean)

Medium-term—BL change (SD)

p-value 1

p-value 2

CAARMS

unusual thought content

Placebo

77

5.6

1.9

−3.8

4.1

0.101

0.638

Omega-3 PUFA

84

4.7

1.4

−3.2

4.5

  

CAARMS

non-bizarre ideas

Placebo

77

6.7

3.0

−3.7

3.9

0.356

0.788

Omega-3 PUFA

83

7.2

3.0

−4.1

4.5

  

CAARMS

perceptual abnormalities

Placebo

77

6.5

3.2

−3.3

3.7

0.972

0.370

Omega-3 PUFA

84

6.3

2.8

−3.5

3.4

  

CAARMS

disorganised speech

 Placebo

77

3.5

0.9

−2.5

3.2

0.705

0.646

Omega-3 PUFA

82

3.7

1.1

−2.6

3.9

  

BPRS total

Placebo

70

41.4

32.1

−9.3

10.0

0.348

0.861

Omega-3 PUFA

71

41.6

32.3

−9.4

10.1

  

BPRS psychotic subscale

Placebo

76

8.5

5.3

−3.2

3.4

0.253

0.871

Omega-3 PUFA

76

8.2

5.3

−2.9

2.9

  

BPRS anxiety

Placebo

76

3.5

2.1

−1.4

1.7

0.862

0.816

Omega-3 PUFA

76

3.2

2.1

−1.1

1.6

  

SANS

Placebo

69

16.4

9.8

−6.6

12.3

0.931

0.495

Omega-3 PUFA

71

18.5

11.5

−7.1

12.3

  

YMRS

Placebo

70

2.7

1.9

−0.8

2.8

0.572

0.286

Omega-3 PUFA

71

3.2

1.5

−1.7

3.7

  

MADRS

Placebo

75

19.5

9.8

−9.7

10.5

0.589

0.663

Omega-3 PUFA

76

20.6

10.9

−9.7

10.4

  

SOFAS

Placebo

89

54.1

69.4

15.3

16.5

0.366

0.518

Omega-3 PUFA

91

52.7

67.5

14.8

18.3

  

Global functioning—social scale

Placebo

76

6.6

7.4

0.8

1.6

0.104

0.483

Omega-3 PUFA

76

6.6

7.2

0.6

1.4

  

Global functioning—role scale

Placebo

76

6.0

7.3

1.3

1.7

0.468

0.385

Omega-3 PUFA

76

6.0

7.1

1.0

1.6

  
  1. n number with baseline and medium-term follow-up data, BL baseline, SD standard deviation of change score, p-value 1 p-value for the interaction between follow-up time and treatment, p-value 2 p-value for treatment, CAARMS Comprehensive Assessment of At-Risk Mental State, BPRS Brief Psychiatric Rating Scale, SANS Scale for the Assessment of Negative Symptoms, MADRS Montgomery-Asberg Depression Rating Scale, YMRS Young Mania Rating Scale, SOFAS Social and Occupational Functioning Scale, PUFA polyunsaturated fatty acids
  2. Note: CAARMS scales were calculated as the sum of the intensity and frequency scales
Back to article page